Iovance Biotherapeutics
IOVA
IOVA
300 hedge funds and large institutions have $1.79B invested in Iovance Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 100 increasing their positions, 85 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
19% less capital invested
Capital invested by funds: $2.21B → $1.79B (-$423M)
21% less call options, than puts
Call options by funds: $28.9M | Put options by funds: $36.4M
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Holders
300
Holding in Top 10
7
Calls
$28.9M
Puts
$36.4M
Top Buyers
| 1 | +$22.4M | |
| 2 | +$19.3M | |
| 3 | +$18.5M | |
| 4 |
Morgan Stanley
New York
|
+$16.8M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$16.2M |
Top Sellers
| 1 | -$41.8M | |
| 2 | -$18.2M | |
| 3 | -$15.8M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$8.83M |